Clovis Oncology Inc股票所在的生物技术行业中，整体跌幅为1.34%。其相关个股中，Madrigal Pharmaceuticals Inc、Axcella Health Inc、Viking Therapeutics Inc涨幅较大，Soleno Therapeutics Inc、Viking Therapeutics Inc、Madrigal Pharmaceuticals Inc较为活跃，换手率分别为252.45%、35.99%、23.77%，振幅较大的相关个股有Axcella Health Inc、Celularity Inc C/Wts 16/07/2026 (To Pur Com)、180 Life Sciences Corp C/Wts 07/11/2025(To Pur Com)，振幅分别为144.97%、64.00%、55.92%。23:06 on December 19, 2022, Beijing time, Clovis Oncology Inc (CLVS.us) shares changed, and the stock price was rapid.Pull up5.00%. As of press time, the stock was trading at US $0.084 per share, with a turnover of 3.41644 million shares.Turnover rate2.36%, amplitude 3.13%.
Recent financial report data show that the Unit has achievedbusiness income30.66 million US dollarsNet profit-US $56.01 millionEarnings per share-$0.39Gross profit$22.06 million, with a price-to-earnings ratio of-0.05.
In terms of agency rating, 100% of the brokerages gave selling advice, while no brokerage gave buy or hold advice.
In the biotechnology industry where Clovis Oncology Inc shares are located, the overall decline was 1.34 per cent. Among its related stocks, Madrigal Pharmaceuticals Inc, Axcella Health Inc and Viking Therapeutics Inc rose a lot, while Soleno Therapeutics Inc, Viking Therapeutics Inc and Madrigal Pharmaceuticals Inc were more active, with turnover rates of 252.45%, 35.99% and 23.77%, respectively. The related stocks with larger amplitudes were Axcella Health Inc, Celularity Inc C/Wts 16 Universe 07Compact 2026 (To Pur Com), 180 Life Sciences Corp C/Wts 07 Universe 11Uniplet 2025 (To Pur Com), with amplitudes of 144.97%, 64.00% and 55.92%, respectively.
About Clovis Oncology Inc: Clovis Oncology Inc is a biopharmaceutical company. It focuses on the acquisition, development and commercialization of cancer drugs in the United States, the European Union and other international markets. The company targets its development program to treat specific cancer populations. Its candidate products include Rucaparib. Rucaparib is an oral small molecule inhibitor of poly (ADP--ribose) polymerase, which is marketed in the United States and is used in two indications for recurrent epithelial ovarian cancer, fallopian cancer or primary peritoneal cancer. The company is divided into two divisions, the United States and outside the United States, according to its geographical region, and most of its revenue comes from the United States.
(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )
